Status:

TERMINATED

Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies

Lead Sponsor:

University of Alabama at Birmingham

Conditions:

Multiple Myeloma

CLL / SLL

Eligibility:

All Genders

19-70 years

Phase:

PHASE2

PHASE3

Brief Summary

A non-myeloablative treatment strategy and uniform selection criteria will enable patients with a variety of low grade B-Cell malignancies to attain long term disease control without unacceptably high...

Detailed Description

Non myeloablative transplant aims to achieve the immunological advantage of graft versus tumor effect as conventional myeloablative therapy without causing high treatment related toxicities. Non myelo...

Eligibility Criteria

Inclusion

  • Stage II or III non-progressive disease Multiple Myeloma.
  • CLL/SLL, and low grade Hodgkin Lymphomas that are in a very good partial response or complete response with non-progressive disease.
  • ≤ 70 years old.
  • Eligible and willing HLA matched related donor.
  • Bilirubin \<2xULN.
  • ALT and AST \<3xULN.
  • LVEF \> 40%.
  • Creatinine Clearance \>40mL/min.
  • Pulmonary function DLCO corrected to ≥ 70%.
  • Minimum performance score of 70%.
  • Platelet count \>130 x103 micro L.
  • LDH ≤1.5xULN.
  • No proceeding co-morbid condition that significantly increases the risk of severe regimen related toxicity.
  • No uncontrolled infections.

Exclusion

  • Age \>70 years old.
  • Performance status \<70%.
  • Uncontrolled infections or is HIV positive
  • Prior malignancies that are felt to have a \<80% probability of being cured.
  • Pregnant, breastfeeding, or refuse to use contraceptive techniques during and for 12 months following transplant.
  • Prior Allograft
  • History of rapidly growing disease at diagnosis or at any progression or have MDS.
  • No eligible and willing HLA matched donor.

Key Trial Info

Start Date :

July 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2013

Estimated Enrollment :

5 Patients enrolled

Trial Details

Trial ID

NCT00714259

Start Date

July 1 2008

End Date

February 1 2013

Last Update

July 24 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Alabama in Birmingham BMT/CT Program Outpatient Clinic

Birmingham, Alabama, United States, 35249-6979

Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies | DecenTrialz